Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.
about
In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patientsComparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group StudyHER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancerQuantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer.Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.Molecular and clinicopathological markers of prognosis in breast cancer.Phospho-PRAS40(Thr246) predicts trastuzumab response in patients with HER2-positive metastatic breast cancer.Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas.Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer.Copy number variation and high expression of DNA topoisomerase II alpha predict worse prognosis of cancer: a meta-analysis.
P2860
Q33812042-353FCCB3-C1A1-4D8A-978C-8DB6923C6865Q36151341-F873A75C-0D21-46F7-BC2C-290B6D1756C0Q36671427-455383C6-0430-42C4-8082-78CCB3FA9882Q36907273-DC775A6F-2DE4-4B42-A1F8-7C29972F8368Q37376754-0BA87E8C-D605-4776-B773-D56E64DCDE1FQ37520405-9B9D4DE5-7F02-4046-A1B7-7C1E5A93227BQ39399933-283F93CF-57E4-4066-BE0F-C06A2801039FQ42289084-3BF70C7C-AE7C-4E26-BE8F-518E97B04BA6Q44358325-CBED8973-3426-4545-BBB1-98A0647A0F3CQ53555841-21373D8D-5170-44F2-808E-2D46FD3756D6Q55396428-E2434C0A-3F05-4476-B974-899E18C6E407
P2860
Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Topoisomerase II alpha gene am ...... ncer treated with trastuzumab.
@ast
Topoisomerase II alpha gene am ...... ncer treated with trastuzumab.
@en
type
label
Topoisomerase II alpha gene am ...... ncer treated with trastuzumab.
@ast
Topoisomerase II alpha gene am ...... ncer treated with trastuzumab.
@en
prefLabel
Topoisomerase II alpha gene am ...... ncer treated with trastuzumab.
@ast
Topoisomerase II alpha gene am ...... ncer treated with trastuzumab.
@en
P2093
P2860
P50
P356
P1476
Topoisomerase II alpha gene am ...... ancer treated with trastuzumab
@en
P2093
Anna Batistatou
Christos Christodoulou
Dimitrios Bafaloukos
Dimosthenis V Skarlos
George Fountzilas
George Pentheroudakis
Ioannis Xanthakis
Irene Papaspirou
Konstantine T Kalogeras
Nikolaos Xiros
P2860
P2888
P356
10.1186/1479-5876-10-212
P577
2012-10-23T00:00:00Z
P5875
P6179
1000711559